Date:11/17/2011

ts" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Such statements include, but are not limited to, any statements relating to the Company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings.  We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact Information:

Investor Relations
Noah D. Beerman, Executive Vice President & Chief Operating Officer
Coronado Biosciences, Inc.
781-238-6619; ir@coronadobio.com

Marcy Nanus, Vice President
The Trout Group, LLC.
646-378-2927; mnanus@troutgroup.com

Media Relations
Dennis S. Dobson Jr., CEO
Dobson Media Group
203-258-0159; dobsonpr@erols.com

'/>"/>

SOURCE Coronado Biosciences Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
2. Coronado Biosciences Closes $25.8M in Series C Financing
3. Coronado Biosciences Files to Become a Public Reporting Company
4. Coronado Biosciences to Present at the Rodman & Renshaw Annual Global Investment Conference
5. Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
6. Coronado Biosciences Reports Third Quarter 2011 Financial Results
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC